Section Arrow
CVM.NYSE-M
- Cel-Sci Corp
Quotes are at least 15-min delayed:2025/09/02 17:32 EDT
After Hours
Last
 12.08
-0.08 (-0.66%)
Bid
11.72
Ask
12.24
High 12.24 
Low 11.5101 
Volume 6197 
Regular Hours
Last
 12.16
+1.73 (+16.59%)
Day High 
12.5 
Prev. Close
10.43 
1-M High
13.4768 
Volume 
419.35K 
Bid
11.72
Ask
12.24
Day Low
10.4 
Open
10.58 
1-M Low
6.84 
Market Cap 
71.78M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 9.96 
20-SMA 9.12 
50-SMA 6.28 
52-W High 39.3 
52-W Low 0.1912 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-9.13/-5.40
Enterprise Value
81.16M
Balance Sheet
Book Value Per Share
1.02
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
400.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.44+0.225+104.65%-- 
After Hours 0.415 -0.025 -5.68%
MNKDMannKind Corp5.74+1.15+25.05%41.45PE
After Hours 5.76 +0.02 +0.35%
CRMDCorMedix14.64-0.19-1.28%19.01PE
After Hours 14.56 -0.08 -0.55%
ADAPAdaptimmune Therapeutics plc0.0578-0.0011-1.87%-- 
After Hours 0.0569 -0.0009 -1.56%
HOTHHoth Therapeutics1.28+0.12+10.34%-- 
After Hours 1.25 -0.03 -2.34%
Quotes are at least 15-min delayed:2025/09/02 17:32 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.